论文部分内容阅读
探讨肾实质性高血压（ＲＰＨ）时肾上腺髓质素水平变化。方法应用放免法测定了１１例肾实质性高血压、３３例原发性高血压（ＥＨ）和２５例正常人的血浆肾上腺髓质素［ＡＤＭ（１３－５２）］、内皮素－１（ＥＴ－１）、血管紧张素Ⅱ（ＡＴⅡ）水平。结果肾实质性高血压患者ＡＤＭ（１３－５２）、ＥＴ－１较ＥＨ和正常人明显增高，ＡＴⅡ较正常人高但与ＥＨ组相似；ＡＤＭ（１３－５２）与ＥＴ－１、ＢＵＮ、平均动脉压（ＭＡＰ）有显著的正相关关系，与ＡＴⅡ无相关性。结论肾实质性高血压患者血浆ＡＤＭ（１３－５２）增高可能是继发于高血压代偿性分泌增多，并可能与肾功能减退代谢障碍、排泄减少有关
To investigate the changes of adrenomedullin in renal parenchymal hypertension (RPH). Methods Radioimmunoassay was used to determine the plasma levels of adrenomedullin (ADM (13-52)) in 11 cases of renal parenchymal hypertension, 33 cases of essential hypertension (EH) and 25 cases of normal controls. Endothelin- -1), angiotensin Ⅱ (ATⅡ) levels. Results The levels of ADM (13-52) and ET-1 in patients with renal parenchymal hypertension were significantly higher than those in EH and normal subjects. ATⅡ was higher than that in normal subjects but similar to that in EH patients. ADM (13-52), ET-1, BUN Arterial pressure (MAP) has a significant positive correlation, and no correlation with AT Ⅱ. Conclusion The increase of plasma ADM (13-52) in patients with renal parenchymal hypertension may be secondary to the increased compensatory secretion of hypertension and may be related to the decline of metabolic dysfunction and excretion of renal dysfunction